Nov 07, 2025
After a brief delay earlier this year, and following its world-first approval in the UK over the summer, Bayer has now secured FDA approval for its novel therapy, expanding the limited range of nonhormonal options available for managing common menopausal symptoms. The FDA has approved Bayer’s dual neurokinin (NK) i...
Read More...
Aug 09, 2025
FemTech, short for “Female Technology,” is a rapidly growing sector in healthcare that focuses on leveraging digital tools like mobile apps, wearables, diagnostics, and telehealth to address women’s health needs. Coined by entrepreneur Ida Tin in 2016, the term captures a movement that began with menstrual tracking...
Read More...
Feb 12, 2025
Alzheimer’s disease currently affects an estimated 50 million people worldwide. This number is projected to rise to 75 million by 2030 and a staggering 131.5 million by 2050, according to Alzheimer's Disease International, spanning all age groups globally. While the exact cause of Alzheimer’s disease remains elusiv...
Read More...
Sep 11, 2024
The concept of FemTech has seen a surge in popularity in recent years. FemTech, short for female technology, focuses on using technology and innovation to address women’s health issues and provide solutions tailored to their unique needs. This field encompasses a broad spectrum of diagnostic tools, products, servic...
Read More...
Feb 21, 2024
Hormone Replacement Therapy (HRT) stands as a big ray of hope for individuals affected by the multifaceted challenges of hormonal imbalances. Defined as the administration of synthetic or natural hormones to supplement or replace the body's own hormonal levels, Hormone Replacement Therapy has emerged as a cornersto...
Read More...
Sep 21, 2019
World Alzheimer’s Day World Alzheimer’s Day takes place on 21 September of every year. World Alzheimer's Day is a campaign to raise awareness and highlight issues faced by people those who are affected by dementia. The exact cause of Alzheimer's disease is not known, although several things are considered to ...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper